免费电话：400-668-6834 | 技术支持：400-168-6834 | 邮箱：info@selleck.cn

Daporinad

目录号：S2799 别名: FK866, APO866

仅限科研使用

Daporinad (FK866, APO866)有效抑制烟酰胺磷酸核糖转移酶(NMPRTase; Nampt)，Daporinad (FK866, APO866) 可引发自噬，无细胞试验中IC50为0.09 nM。Phase 1/2。

CAS: 658084-64-1

规格	价格	库存
5mg	RMB 737.65	现货
25mg	RMB 3025.95	现货
50mg	RMB 4662.84	现货
大包装	有超大折扣

今日订购，明日送达全国免运费分装免费分装成小规格产品（单支最小为1mg）如1支10mg产品可分装为10支1mg产品全国免费电话：400-668-6834 \| Email：info@selleck.cn

客户使用Selleck生产的Daporinad 发表文献50篇：

产品安全说明书

Transferase抑制剂选择性比较

生物活性

产品描述

Daporinad (FK866, APO866)有效抑制烟酰胺磷酸核糖转移酶(NMPRTase; Nampt)，Daporinad (FK866, APO866) 可引发自噬，无细胞试验中IC50为0.09 nM。Phase 1/2。

靶点

NMPRTase ^[5]
(Cell-free assay)

0.4 nM(Ki)

体外研究

APO866在0.09-27 nM的低浓度范围内会在41血液恶性肿瘤细胞中诱导产生细胞毒性，包括急性髓细胞白血病[AML]，急性淋巴细胞白血病 [ALL], 套细胞淋巴瘤[MCL], 慢性淋巴细胞白血病[CLL]和 T细胞淋巴瘤，这种毒性具有剂量依赖特性. APO866在0-10 nM的低浓度范围内会诱导细胞死亡，这一效果与线粒体膜去极化有关而与半胱天冬酶的激活无关。APO866在0-10 nM的浓度范围内会诱导胞内NAD 和 ATP 的损耗和多种血液肿瘤细胞的死亡，这一效果具有剂量依赖特性^[1] 。10 nM APO866 会抑制HFFF2细胞内 PBEF诱导的 MMP-3, CCL2和CXCL8 的分泌 ^[2]。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

SH-SY5Y	MX3DfZRwfG:6aXPpeJkh[XO\|YYm=			NE[4[5JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iC2b4ThcEBk\WyudXzhdkBPSURqUDmgcIV3\WxuIFnDOVAhRSByLkCwNFUh\|ryPLh?=	NITXZ5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2NVE5Oyd-MUm5OlEyQDN:L3G+
SH-SY5Y	MVLDfZRwfG:6aXPpeJkh[XO\|YYm=		MUC0PEBpenN?	MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjByMUeg{txONg>?	NYrzN3RxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OlEyQDNpPkG5PVYyOTh\|PD;hQi=>
HT1080	NYrVZnBJS3m2b4TvfIlkcXS7IHHzd4F6		MXe2JIRigXN?	MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWFExQDBiY3XscJMh[W[2ZYKgOkBl[Xm\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvOTZizszNMi=>	NH75WWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOzNFAyPSd-MkGzN\|AxOTV:L3G+
A549	NVuzblNFS3m2b4TvfIlkcXS7IHHzd4F6		MmHVOkBl[Xm\|	MkfXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC2JIRigXNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE4yPiEQvF2u	M3jBVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{OwNFE2Lz5{MUOzNFAyPTxxYU6=
HCT116	MnG4R5l1d3SxeHnjbZR6KGG\|c3H5		M17SclYh\GG7cx?=	MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOkBl[Xm\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvOTZizszNMi=>	NUDhemZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzN\|AxOTVpPkKxN\|MxODF3PD;hQi=>
SNU638	MmLOR5l1d3SxeHnjbZR6KGG\|c3H5		MYC2JIRigXN?	NXTTdnBQS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW06XNkO4JINmdGy\|IHHmeIVzKDZiZHH5d{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkG2JO69VS5?	M2DXT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{OwNFE2Lz5{MUOzNFAyPTxxYU6=
MCF7	NVHwXJN3SW62aYT1cY9zKGG\|c3H5	NEfuO4EyOCC3TR?=	M17BOVYh\GG7cx?=	NUTGT5pbSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BifCBzMDD1UUBi\nSncjC2JIRigXNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE43QCEQvF2u	M{fEe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{OwNFE2Lz5{MUOzNFAyPTxxYU6=
K562	NX[1b3ZmS3m2b4TvfIlkcXS7IHHzd4F6		NXfUbI9PPiCmYYnz	NVvuZVlMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCjZoTldkA3KGSjeYOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOjBizszNMi=>	MnPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|M{CwNVUoRjJzM{OwNFE2RC:jPh?=
A2780	MWLDfZRwfG:6aXPpeJkh[XO\|YYm=		NVLpOnM2PzJiaILz	MnnQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvODBzIN88UU4>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzN{e4OEc,OjN4MUe3PFQ9N2F-
NYH	M2XoU2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MWKzJJdm\Wu\|	NWTpPZdiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVlmKIHPlcIx{KGGodHXyJFMhf2Wna4OgZpkh[2yxbn;n[Y5q[yC\|dYL2bZZidCCjc4PhfUwhVER3MDC9JFAvODBzNTFOwG0v	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ5OUmxOUc,OjN4N{m5NVU9N2F-
K562	M{n3UmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MYW5OkBpenN?	M2POOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMh[W[2ZYKgPVYhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODB5MjFOwG0v	M2PrUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nke5PVE2Lz5{M{[3PVkyPTxxYU6=
A2780	NULSUJV3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWe3NkBpenN?	NUXpSWZrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhW1KELXLhd4VlKG2rY4LvdIxifGVicnXh[IVzKGGwYXz5d4l{NCCLQ{WwJF0hOC5yMEGg{txONg>?	MmGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUmxNVgoRjJ\|OEW5NVE5RC:jPh?=
NYH	NVfienRDS3m2b4TvfIlkcXS7IHHzd4F6			MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOXWgh[2WubIOgZpkh[2yxbn;n[Y5q[yCjc4PhfUwhUUN3MDC9JFAvODBzNTFOwG0v	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NEC4Okc,OjRzNkSwPFY9N2F-
A2780	MUnDfZRwfG:6aXPpeJkh[XO\|YYm=		MmDGO\|IhcHK\|	MljGR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KFeVVD2xJIF{e2G7LDDJR\|UxKD1iMD6wNFE3KM7:TT6=	NYDPU3oyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlQxQDZpPkK0NVY1ODh4PD;hQi=>
HepG2	M1q3V2Z2dmO2aX;uJIF{e2G7		NHPVblkyKGi{	NFjpbHZKdmirYnn0bY9vKG:oIF7BUXBVKGmwIHj1cYFvKEincFeyJINmdGy\|IIXzbY5oKFtzNFPdMY5q[2:2aX7hcYll\S:SUmDQJIF{KHO3YoP0doF1\SCjc4Pld5Nm\CCjczDmc5Ju[XSrb36gc4YhYzF2Q22tcolkd3SrbnHtbYRmKG2xbn;ueYNt\W:2aXTlJIFnfGW{IEGgbJIh[nlibHnxeYllKHOlaX70bYxt[XSrb36gZ492dnSrbnegZY5idHm\|aYOsJGlEPTBiPTCwMlAxOjJizszNMi=>	MkL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNkSwPFYoRjJ2MU[0NFg3RC:jPh?=
PC3	MoLsR5l1d3SxeHnjbZR6KGG\|c3H5			NEfHWoVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[nliY3zvco9o\W6rYzDhd5NigSxiSVO1NEA:KDBwMECzPEDPxE1w	NGTMPGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OFA5Pid-MkSxOlQxQDZ:L3G+
A2780	NXT1SYk{S3m2b4TvfIlkcXS7IHHzd4F6			NWO5UXNES3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNiYomgZ4xwdm:pZX7pZ{Bie3OjeTygTWM2OCB;IECuNFA2PyEQvF2u	MoDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNkSwPFYoRjJ2MU[0NFg3RC:jPh?=
A431	NH7FTnpEgXSxdH;4bYNqfHliYYPzZZk>			NVSwOplMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR\|MTDj[YxteyCkeTDjcI9vd2enbnnjJIF{e2G7LDDJR\|UxKD1iMD6wNFYyKM7:TT6=	NF\ycYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OFA5Pid-MkSxOlQxQDZ:L3G+
MCF-7	NWHTWlVIS3m2b4TvfIlkcXS7IHHzd4F6		NGjLVnM4OiCqcoO=	MkS0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHNTdiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KFeVVD2xJIF{e2G7LDDJR\|UxKD1iMD6wNFc1KM7:TT6=	NV;MS5RVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlQxQDZpPkK0NVY1ODh4PD;hQi=>
MCF7	MV;DfZRwfG:6aXPpeJkh[XO\|YYm=			M1Wy[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[nliY3zvco9o\W6rYzDhd5NigSxiSVO1NEA:KDBwMEC4OEDPxE1w	M3j4dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[0NFg3Lz5{NEG2OFA5PjxxYU6=
HCT116	MmT0R5l1d3SxeHnjbZR6KGG\|c3H5		MmLGO\|IhcHK\|	MkXPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCZU2StNUBie3OjeTygTWM2OCB;IECuNFExQSEQvF2u	NV7sXldnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlQxQDZpPkK0NVY1ODh4PD;hQi=>
SKOV3	M2\HRWN6fG:2b4jpZ4l1gSCjc4PhfS=>			M2HaTGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMV1Z\|IHPlcIx{KGK7IHPsc45w\2WwaXOgZZN{[XluIFnDOVAhRSByLkKxNUDPxE1w	MlfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNkSwPFYoRjJ2MU[0NFg3RC:jPh?=
HCT116	MWTDfZRwfG:6aXPpeJkh[XO\|YYm=		NUO0fmxGPzJiaILz	MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBCWE96Nk[tdoV{cXO2YX70JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhX1OWLUGgZZN{[XluIFnDOVAhRSByLkm0OkDPxE1w	NVPtRWVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlQxQDZpPkK0NVY1ODh4PD;hQi=>
A2780	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Ml22O\|IhcHK\|	NX7iXm5kSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiSVO1NEA:KDBwMECxJO69VS5?	NVyzNGVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFU1OTlpPkK0OFA2PDF7PD;hQi=>
A2780	NIXHO3ZHfW6ldHnvckBie3OjeR?=		NEnP[lU4OiCqcoO=	NGrtSIRKdmirYnn0bY9vKG:oIF7BUXBVKGmwIHj1cYFvKEF{N{iwJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlAxOSEQvF2u	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV2MUK3NUc,Ojd3NEGyO\|E9N2F-
DE3	M33U[mZ2dmO2aX;uJIF{e2G7		NFfCfIYyPSCvaX7z	M33pU2lvcGmkaYTpc44hd2ZiaIXtZY4h\nWubDDs[Y5ofGhiQz30[ZJucW6jbDDIbZM3NXSjZ3fl[EBPSU2SVDDlfJBz\XO\|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBTd3OndIThJEhFTTNrIHPlcIx{KHW\|aX7nJI5q[2:2aX7hcYll\SCjczDzeYJ{fHKjdHWgbY5kfWKjdHXkJIZweiBzNTDtbY5{KHC{aX;yJJRwKHO3YoP0doF1\SCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA{OCCvaX7zJIlvKHC{ZYPlcoNmKG:oIGDSVHAtKEmFNUCgQUAxNjByMzFOwG0v	M{D2OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUSxNlcyLz5{N{W0NVI4OTxxYU6=
SH-SY5Y	MmL6R5l1d3SxeHnjbZR6KGG\|c3H5		MXO1OkBpenN?	Ml[xR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2guW1l3WTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNU[gbJJ{KGK7IF3UWEBie3OjeTygSWM2OCB;IECuNFA{PCEQvF2u	NFP1fIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG2OVc1Oid-MkixOlU4PDJ:L3G+
A2780	MVXDfZRwfG:6aXPpeJkh[XO\|YYm=			MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHluIFnDOVAhRSByLkCwOFIh\|ryPLh?=	MmG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNkW3OFIoRjJ6MU[1O\|QzRC:jPh?=
PC3	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NXGyTGxvPSCmYYnz	M4jlcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBqdmO3YnH0[YQh\m:{IEWg[IF6eyCkeTDD[YxtNXSrdHXyJGdtdyC{ZXHn[Y51KGKjc3XkJIF{e2G7LDDJR\|UxKD1iMD6wNFU4KM7:TT6=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZzMEm4OEc,Ojh4MUC5PFQ9N2F-
HepG2	NHjndJJEgXSxdH;4bYNqfHliYYPzZZk>		M2fLeVczKGi{cx?=	MVTDfZRwfG:6aXPpeJkhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlg6KM7:TT6=	NXTte\|lvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4PFU5OzRpPkK4PFg2QDN2PD;hQi=>
MDA-MB-231	MoHBR5l1d3SxeHnjbZR6KGG\|c3H5		MX23NkBpenN?	NXm2T3BES3m2b4TvfIlkcXS7IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxMlMh\|ryPLh?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh6NUizOEc,Ojh6OEW4N\|Q9N2F-
HCT116	NYDlUVBnS3m2b4TvfIlkcXS7IHHzd4F6		M2DPUFczKGi{cx?=	MmrPR5l1d3SxeHnjbZR6KGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEvPiEQvF2u	NVLwNVVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4PFU5OzRpPkK4PFg2QDN2PD;hQi=>
HepG2	M4C3SWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NHvlcGE4OiCqcoO=	NHywbldEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLki5JO69VS5?	Mn\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|NEi4NFgoRjJ7M{S4PFA5RC:jPh?=
HCT116	NGXxcJdEgXSxdH;4bYNqfHliYYPzZZk>		NUDFRXN2PzJiaILz	MlvSR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDndo94fGhiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwNjFOwG0v	NIXPcZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUO0PFgxQCd-MkmzOFg5ODh:L3G+
A549	NE\wUmtEgXSxdH;4bYNqfHliYYPzZZk>		NVnDNVJ5PzJiaILz	MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCpcn;3eIgh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFMvPyEQvF2u	NH\zUVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUO0PFgxQCd-MkmzOFg5ODh:L3G+
SH-SY5Y	M3;ke2F2fG:yaHHnfUBie3OjeR?=		M33LRlQxKGi{cx?=	NEK1VYpKdmS3Y4Tpc44hd2ZiYYX0c5Bp[We7IHnuJIh2dWGwIGPIMXN[PVliY3XscJMh[XO\|ZYPz[YQh[XNiTFOzM5Bpd3OyaH;0bYR6dGW2aHHuc4xidWmwZTDjc5VxdGmwZzDh[pRmeiB2MDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NYjCZ2IyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OlEyQDNpPkG5PVYyOTh\|PD;hQi=>
MCF7	M375bmFvfGm2dX3vdkBie3OjeR?=		MkL5OkBl[Xm\|	M{HKe2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNjDkZZl{KGK7IGPSRkBie3OjeR?=	NYLuVnRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzN\|AxOTVpPkKxN\|MxODF3PD;hQi=>
MDCK	MV3GeY5kfGmxbjDhd5NigQ>?	NHzqS\|gyOCC3TR?=		MmPlRZBx[XKnboSgdIVzdWWjYnnsbZR6KGGlcn;zd{BieGmlYXygeI8h[mG\|b3zheIVz[Wxic3nk[UBqdiCmb3egUWREUyClZXzsd{BifCBzMDD1UUBjgSCOQz3NV{9OWyCjbnHsfZNqew>?	NXXxW2RMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OVkyOThpPkKzPFU6OTF6PD;hQi=>
DU145	NYrNTXZFS3m2b4TvfIlkcXS7IHHzd4F6			NIfibJpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCkeTDjcI9vd2enbnnjJIF{e2G7	M1v0flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[0NFg3Lz5{NEG2OFA5PjxxYU6=
MCF7	MmewR5l1d3SxeHnjbZR6KGG\|c3H5		MVK5OkBpenN?	NF65OIlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFk3KGi{czDifUBkdG:wb3flcolkKGG\|c3H5	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NEC4Okc,OjRzNkSwPFY9N2F-
HCT116	M{fTVmZ2dmO2aX;uJIF{e2G7			NIPTd41T\XOrc4ThcoNmKG[jY4TvdkwhemG2aX:gc4YhUUN3MDDmc5IhSVCROE[2MZJme2m\|dHHueEBpfW2jbjDIR3QyOTZiY3XscJMhfG9iSVO1NEBnd3JiaIXtZY4hUEOWMUG2JINmdGy\|	M2XjOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[0NFg3Lz5{NEG2OFA5PjxxYU6=
A2780	NV7hdnRTSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mmm0O\|IhcHK\|	NVLvXFlbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSCrbjDwdoV{\W6lZTDv[kBvcWOxdHnuZY1q\GVibX;uc452[2ynb4Tp[IU>	M2PHXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEC1OFE6Lz5{NESwOVQyQTxxYU6=
Sf9	NGf0Z4FHfW6ldHnvckBie3OjeR?=		NUSwTWNLOzBibXnudy=>	M{DJcGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSg[pVtdCCuZX7neIghcHWvYX6gR{11\XKvaX7hcEBJcXNxZnzh[{11[WepZXSgTGRCSzFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMh[W[2ZYKgN\|AhdWmwczDifUBndHWxcnXzZ4Vv[2ViYYPzZZk>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN2OEiwPEc,Ojl\|NEi4NFg9N2F-

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	SIRT1 p-AMPK / AMPK / p-EIF2A / EIF2A / p-4EBP1 / 4EBP1 AKT / pAKT(Ser-473) / mTOR / p-mTOR(Ser-2448)	29905535 29541451 26542945
Immunofluorescence	pMLKL phGSK3β ph-β-catenin	29996103 22207684
Growth inhibition assay	Cell viability	27462772

体内研究

用C.B.-17 SCID 小鼠建立人急性髓细胞白血病，淋巴母细胞淋巴瘤和白血病的异种移植模型，腹腔注射APO866 ，一天两次，一次20 mg/kg 一周4天, 重复三周以上可以抑制肿瘤生长。 ^[1]对于携带CIA的小鼠， 0.12 mg/kg/小时剂量的 APO866 可以通过抑制PBEF 来防止关节破坏和白细胞浸润^[2]。

细胞实验： ^[1]	Cell lines: 41血液恶性肿瘤细胞系 Concentrations: 0 - 10 nM Incubation Time: 72 小时或 96小时 Method: MTT 分析流程, 细胞按每毫升0.5 &time 10⁶ 个的密度接种到96孔板，接种三份。将APO866 (0.01 nM-100 nM) 加到50 μL 培养基中, 空白培养基作为对照。孵育 72或 96 小时后每孔加入15 μL 染料溶液继续孵育 4 小时。然后每孔加入100 μL 终止液孵育 1小时，用分光光度计测量570 nm 处吸光度。台盼蓝染色分析流程, 细胞按每孔0.5 &time10⁵ 个接种到6孔板，每孔加入1 mL培养基，在含有或缺少 APO866的情况下孵育 96 小时。每孔取10μL 细胞样品与10 μL 台盼蓝孵育1分钟（体积比1:1）。细胞存活情况通过计算未染色的细胞个数来获得。
动物实验： ^[1]	Animal Models: 人急性髓细胞白血病，淋巴瘤以及白血病的C.B.-17 SCID 小鼠异种移植模型 Dosages: 20 mg/kg Administration: 腹腔注射一天两次，连续四天，重复3周以上

参考文献	[1] Nahimana A, et al. Blood, 2009, 113(14), 3276-3286. [2] Evans L, et al. Arthritis Rheum, 2011, 63(7), 1866-1877. [3] Olesen UH, et al. Mol Cancer Ther, 2010, 9(6), 1609-1617. [4] Zoppoli G, et al. Exp Hematol, 2010, 38(11), 979-988. [5] Hasmann M, et al. Cancer Res. 2003 , 63(21):7436-42. + 展开

溶解度（25°C）

体外


体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O 点击购买： PEG300 Tween 80	4mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量	391.51
化学式	C₂₄H₂₉N₃O₂
CAS号	658084-64-1
储存条件	3年	-20°C	粉状
储存条件	2年	-80°C	溶于溶剂

Download Daporinad SDF

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

临床试验信息

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00435084	Completed	Drug: APO866	B-cell Chronic Lymphocytic Leukemia	Onxeo	February 2007	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

* 姓名 请输入您的姓名

* 邮箱 请输入您的邮箱地址 请输入一个有效的邮箱地址

电话

* 留言内容 请写点东西给我们

常见问题及建议解决方法

问题 1:
We are considering the use of S2799 for in vivo injections, Any suggestions for the formula?

回答：
The vehicle we recommend for S2799 in vivo study is 45% Propylene glycol (dissolve first) +5% Tween 80+ddH2O. You can dissolve the compound in Propylene glycol first and then dilute with water with Tween 80. The solution is clear and can be used for injection.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):